Efficacy of anti IL23 and anti IL17 after adalimumab failure in psoriatic patients.

Luca MastorinoS SuscaC CaritiN SliquiniA VerroneE StroppianaM OrtoncelliP DapavoSimone Ribero Pietro Quaglino

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Anti-IL 23 and anti-IL 17 agents are not significantly different in terms of efficacy in bio-naive patients or as second-line therapy after failure with a biosimilar or originator adalimumab.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
rheumatoid arthritis
ejection fraction
prognostic factors
stem cells
smoking cessation